NEW YORK, July 26, 2008 NYU Langone Medical Center researchers have long been making important contributions to the understanding of Alzheimer's disease. They were among the first to characterize amyloid, the plaque-forming protein implicated in Alzheimer's, and the first to describe a genetic mutation in a familial form of the disease. They also developed the first successful intervention program to reduce the need for placing patients in nursing homes and alleviate caregivers' depression.
At the 2008 ICAD meeting, NYU Langone Medical Center researchers are presenting a wide range of findings from both clinical studies using state-of-the-art methods to discern the earliest sign of Alzheimer's and from animal studies aimed at understanding how amyloid causes neuronal dysfunction in the brain. All of this research helps advance the understanding of Alzheimer's, which now afflicts more than 5 million Americans. A better understanding, it is hoped, will lead to more effective therapies that will slow the progression of the disease and ultimately to ways to prevent its onset.
The following news tips are based on poster and oral presentations at the Alzheimer's Association 2008 International Conference to be held in Chicago from July 26 to July 31. Each presentation is embargoed for a specific date and time.
Brain Atrophy and Biomarkers May Help Identify People at Risk for Alzheimer's
Susan de Santi, Ph.D., Associate Professor, Department of Psychiatry, NYU Langone Medical Center
EMBARGOED FOR RELEASE UNTIL TUESDAY, July 29, 2008 at 12:30 p.m. CT
By combining MRI brain scans and measurements of certain compounds in the cerebrospinal fluid, NYU researchers were able to distinguish individuals who would develop Alzheimer's disease over a two-year period. In a study of 23 people, they found atrophy in areas of the brain involved in learning and memory, and significantly higher CSF levels of phosphorylated ta
|Contact: Bob Brody|
NYU Langone Medical Center / New York University School of Medicine